Novonesis Overview
- Year Founded
-
1873
- Status
-
Public
- Employees
-
11,641
- Stock Symbol
-
NSIS B
- Investments
-
43
- Share Price
-
$64.58
- (As of Thursday Closing)
Novonesis General Information
Description
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
Contact Information
Website
www.novonesis.comCorporate Office
- Biologiens Vej 2
- 2800 Lyngby
- Denmark
Corporate Office
- Biologiens Vej 2
- 2800 Lyngby
- Denmark
Novonesis Stock Performance
As of 19-Nov-2026, Novonesis’s stock price is $64.58. Its current market cap is $30.1B with 466M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $64.58 | $66.33 | $51.66 - $72.33 | $30.1B | 466M | 648K | $1.70 |
Novonesis Financials Summary
As of 30-Sep-2026, Novonesis has a trailing 12-month revenue of $5.08B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 32,808,998 | 33,213,606 | 28,273,108 | 15,204,282 |
| Revenue | 5,079,878 | 4,689,798 | 4,148,226 | 2,599,362 |
| EBITDA | 1,094,587 | 1,540,292 | 1,093,677 | 781,475 |
| Net Income | 791,807 | 658,304 | 330,906 | 439,214 |
| Total Assets | 19,081,332 | 19,203,961 | 15,812,114 | 4,210,910 |
| Total Debt | 3,549,931 | 3,530,199 | 1,869,700 | 1,154,037 |
Novonesis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Novonesis Comparisons
Industry
Financing
Details
Novonesis Competitors (18)
One of Novonesis’s 18 competitors is Arzeda, a Venture Capital-Backed company based in Seattle, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arzeda | Venture Capital-Backed | Seattle, WA | ||||
| Chr. Hansen | Formerly PE-Backed | Hoersholm, Denmark | ||||
| Advanced Enzyme Technologies | Formerly PE-Backed | Thane, India | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Evogene | Formerly VC-backed | Rehovot, Israel |
Novonesis Patents
Novonesis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026077488-A2 | Use of protease to degrade animal hairballs | Pending | 27-Jun-2025 | ||
| WO-2026077488-A3 | Use of protease to degrade animal hairballs | Pending | 27-Jun-2025 | ||
| WO-2026234237-A1 | Fermentation method | Pending | 09-May-2025 | ||
| WO-2026233909-A1 | Method for packaging a meat product | Pending | 05-May-2025 | ||
| WO-2026219898-A2 | Citrate-deficient lacticaseibacillus rhamnosus strains and uses thereof | Pending | 16-Apr-2025 | A23C9/1234 |
Novonesis Signals
Novonesis Investments & Acquisitions (43)
Novonesis’s most recent deal was a Merger/Acquisition with Microbiogen. The deal was made on 01-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Microbiogen | 01-Oct-2026 | Merger/Acquisition | Coal and Consumable Fuels Equipment | ||
| TurtleTree | 08-Jul-2026 | Later Stage VC | Food Products | ||
| Meihua Group (Production Facility in Rayong, Thailand) | 08-Apr-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Feed Enzyme Alliance | 02-Jun-2025 | Merger/Acquisition | Food Products | ||
| Chr. Hansen | 29-Jan-2024 | Merger/Acquisition | Biotechnology |
Novonesis ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
16.31 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Chemicals
Industry
of 503
Rank
Percentile
Specialty Chemicals
Subindustry
of 165
Rank
Percentile
Novonesis Exits (10)
Novonesis’s most recent exit was on 13-Dec-2018 from Plant Response. The exit was categorized as with 7 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Plant Response | 13-Dec-2018 | Completed |
|
||
| Maabjerg Energy Center BioGas | 04-Apr-2017 | Completed |
|
||
| AgBiome | 20-Aug-2015 | Completed |
|
||
| Plant Response | 07-Aug-2015 | Completed |
|
||
| AgBiome | 14-Nov-2014 | Early Stage VC | Completed |
|
Novonesis Affiliates
Subsidiaries (11)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Jupiter Beteiligungsgesellschaft mbH | Nienburg/Weser, Germany | 2020 | |
| Microbiome Labs | Franklinton, NC | 2012 | |
| Novonesis Plant Biosolutions | Kongens Lyngby, Denmark | 2007 | |
| Synergia Life Sciences | Mumbai, India | 2004 | |
| Novozymes France | Le Pecq, France | 2001 |
Novonesis FAQs
-
When was Novonesis founded?
Novonesis was founded in 1873.
-
Where is Novonesis headquartered?
Novonesis is headquartered in Lyngby, Denmark.
-
What is the size of Novonesis?
Novonesis has 11,641 total employees.
-
What industry is Novonesis in?
Novonesis’s primary industry is Biotechnology.
-
Is Novonesis a private or public company?
Novonesis is a Public company.
-
What is Novonesis’s stock symbol?
The ticker symbol for Novonesis is NSIS B.
-
What is the current stock price of Novonesis?
As of 19-Nov-2026 the stock price of Novonesis is $64.58.
-
What is the current market cap of Novonesis?
The current market capitalization of Novonesis is $30.1B.
-
What is Novonesis’s current revenue?
The trailing twelve month revenue for Novonesis is $5.08B.
-
Who are Novonesis’s competitors?
Arzeda, Chr. Hansen, Advanced Enzyme Technologies, GSK, and Evogene are some of the 18 competitors of Novonesis.
-
What is Novonesis’s annual earnings per share (EPS)?
Novonesis’s EPS for 12 months was $1.70.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process